<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">Iron overload</z:e> may represent an additional clinical problem in patients with <z:hpo ids='HP_0002863'>Myelodysplastic Syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), with recent data suggesting prognostic implications </plain></SENT>
<SENT sid="1" pm="."><plain>Beyond red blood cells transfusions, dysregulation of hepcidin, the key iron hormone, may play a role, but studies until now have been hampered by technical problems </plain></SENT>
<SENT sid="2" pm="."><plain>Using a recently validated assay, we measured serum hepcidin in 113 patients with different <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes </plain></SENT>
<SENT sid="3" pm="."><plain>Mean hepcidin levels were consistently <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> across different <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes, with the lowest levels in <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 1.43 nM) and the highest in <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 11.3 nM) or in <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>, 10.04 nM) (P = 0.003 by ANOVA) </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes remained significant predictors of hepcidin in multivariate analyses adjusted for ferritin and transfusion history </plain></SENT>
<SENT sid="5" pm="."><plain>Consistently with current knowledge on hepcidin action/regulation, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> patients had the highest levels of toxic non-transferrin-bound-iron, while <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients had substantial elevation of C-Reactive Protein as compared to other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes, and showed lost of homeostatic regulation by iron </plain></SENT>
<SENT sid="6" pm="."><plain>Growth differentiation factor 15 did not appear as a primary hepcidin regulator in this series </plain></SENT>
<SENT sid="7" pm="."><plain>If confirmed, these results may help to calibrate future treatments with chelating agents and/or hepcidin modulators in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>